Announced
Completed
Synopsis
Bioventus, which develops and markets orthopedic therapies and diagnostic tools, completed a $15m investment in CartiHeal, an Israel-based developer of the proprietary Agili™-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. "We are pleased Bioventus continues to see value in the Agili-C implant and is making a greater investment to support the completion of the IDE study. We look forward to the work ahead and a successful application for PMA approval," Nir Altschuler, CartiHeal Founder and CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.